Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NICIR: Oral vs IV Hydration for CIN Prevention
NCT02872155Phase 3Completed
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial (2 arms). Primary endpoint: Proportion of contrast induced nephropathy. Started Jul 2017; status: completed.
Beyond the preview
Go deeper on NCT02872155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02872155.